HIGHBuilt-inGeographic
56.7%
international sales
“10-K Item 1: 'Sales outside of the U.S. accounted for 56.7% of our consolidated net sales in 2025'”
WST · Concentration risk · 10-K extracted
West Pharmaceutical Services, I (WST) concentration risks
Updated
The most significant concentration West Pharmaceutical Services, I discloses is international sales at 56.7%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: West Pharmaceutical Services, I’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 4 disclosed concentrations
HIGH2
MEDIUM1
LOW1
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
single-source raw materials
“10-K Item 1A: 'many components and raw materials are available and/or purchased only from a single supplier'”
MEDIUMOutside partyCustomer
47.6%
top ten customers
“10-K Item 1: 'Our ten largest customers accounted for 47.6% of our consolidated net sales in 2025'”
LOWOutside partyCustomer
15.8%
one customer >10% of net sales
“10-K Item 1: 'one of these customers individually accounted for more than 10% of consolidated net sales, at 15.8% or $485.9 million'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentrations span geography, supply, and customers, with two high-share exposures. The largest is geographic: sales outside the U.S. were 56.7% of consolidated net sales — a high share by disclosed size and structural, reflecting a globally distributed customer base. The second high-share exposure is supply-side: many components and raw materials are available only from a single supplier, a dependency where a disruption at one source could interrupt production. Customer concentration is more moderate: the ten largest customers accounted for 47.6% of consolidated net sales, a medium-share dependency, and a single customer individually represented 15.8% of consolidated net sales, a low-share dependency on its own. Netting these out, the international revenue weighting and the single-source supply reliance are the two structurally large exposures, while the customer book is concentrated but not dominated by any one account. The single-source inputs and the largest customer are the lines most worth monitoring.
For the engine’s reasoning on WST’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Instruments & Supplies
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| WST● | West Pharmaceutical Services, I | 2 | 1 | 1 | 4 |
| BAX | Baxter International Inc. | 1 | 2 | 0 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| BDX | Becton, Dickinson and Company | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVTR | Avantor, Inc. | 1 | 0 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.